Africa to get doses of Pfizer-BioNTech COVID-19 vaccine

By The Science Advisory Board staff writers

Pfizer and BioNTech have signed a letter of intent with South Africa-based Biovac Institute to manufacture and distribute the companies' COVID-19 vaccine within the African Union.

By the end of 2021, Pfizer and BioNTech expect that Biovac's facility in Cape Town will be incorporated into the vaccine supply chain. Biovac will obtain drug substance from facilities in Europe, with the manufacturing of finished doses to be completed in 2022.

At full operational capacity, the annual production will exceed 100 million finished doses per year, according to the company. All doses will be distributed exclusively within the 55 member states that make up the African Union.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?